Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:02 PM
Ignite Modification Date:
2025-12-24 @ 7:02 PM
NCT ID:
NCT00210457
Eligibility Criteria:
Inclusion Criteria:
* Patient having documentation supporting diagnosis of active acromegaly in one of the following definitions:
* patient having received neither somatostatin analogue nor dopaminergic agonist within the previous 12 weeks and having an IGF-1 level at least 1.3 times the upper limit of the age-adjusted normal range,
* patient being treated with a somatostatin analogue (other than lanreotide autogel) or a dopaminergic agonist when attending the first visit and having at the end of the wash-out period an IGF-1 level at least 1.3 times the upper limit of the age-adjusted normal range.
Exclusion Criteria:
* Patient having had pituitary surgery within the previous 3 months
* Patient having received radiotherapy for acromegaly disease within the previous 36 months
* Patient being predicted to require pituitary surgery (adenomectomy) or receive radiotherapy during the study period
* Patient having received lanreotide autogel at any time before the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00210457
Study Brief:
Protocol Section:
NCT00210457